Open Access

Primary yolk sac tumor of seminal vesicle: a case report and literature review

Contributed equally
World Journal of Surgical Oncology201210:189

https://doi.org/10.1186/1477-7819-10-189

Received: 12 June 2012

Accepted: 11 August 2012

Published: 14 September 2012

Abstract

Background

Yolk sac tumor (endodermal sinus tumor) is a rare malignant germ cell tumor arising in the testis or ovary. Extragonadal yolk sac tumor is even rarer and has only been described in case reports. Due to the rarity of the tumors, the appropriately optimal treatment remains unclear. We report a case of yolk sac tumor in the seminal vesicle.

Case

A 38-year-old Asian male presented with gross hematuria and hemospermia. Transrectal ultrasound scan showed a solid mass in the left seminal vesicle and the scrotal sonography showed no abnormalities. Bilateral seminal vesicles were resected, and histopathological examination showed a typical pattern of yolk sac tumor (YST). The patient responded poorly to comprehensive treatment of radiotherapy, chemotherapy and surgeries, developed systemic multiple metastases, and died of cachexia one and half years after diagnosis.

Keywords

Yolk sac tumor Seminal vesicle Extragonadal

Background

Yolk sac tumor (YST, also called endodermal sinus tumor) most frequently occurs in the gonads and has a poor prognosis, if not treated aggressively [1].

Extragonadal yolk sac tumor (YST) is rare, and the most common sites of origin are, in order of frequency, the mediastinum, the retroperitoneum, the sacrococcygeal region and the pineal gland [2]. Due to the rarity of this tumor, the reported cases were treated by varied surgeries with or without adjuvant therapy. Thus, the optimal treatment remains unclear. To add to the literature, we report a case of yolk sac tumor originating in the left seminal vesicle.

Case presentation

A 38-year-old Asian male presented to his urologist with gross hematuria and hemospermia of a half-year duration. The remainder of his physical examination, medical history and surgical history were unremarkable. He had no history of cryptorchidism, testicular swelling or testicular atrophy, and no family history of testicular cancer. A transrectal ultrasound scan performed on the day of presentation showed a solid mass of the left seminal vesicle. A puncture biopsy of the left seminal vesicle confirmed diagnosis of germ cell tumor. No tumorous lesions were found in other sites. At presentation, levels of serum tumor markers were obtained: α-fetoprotein (AFP) was found to be elevated to 1,740.9 ug/l (normal less than 10 ng/ml); serum β-human chorionic gonadotropin (β-hCG) (normal less than 10 mIU/ml) and prostate-specific antigen (PSA) (normal less than 4.0 ng/ml) were within normal range. The patient was given four cycles of chemotherapy consisting of bleomycin (15 mg D-2, 9, and 16), cisplatin (30 mg/m2 for four consecutive days), and etoposide (100 mg/m2 for four consecutive days). After the chemotherapy, serum AFP was found to be decreased to 58.09 ug/l, and the symptom of hemospermia disappeared.

The patient was then transferred to our hospital. He had normal testes on palpation. And a scrotal sonography was performed and revealed no abnormalities. Magnetic resonance imaging (MRI) reported an abnormal signal mass in the left seminal vesicle (Figure 1). Positron emission tomography/computed tomography (PET/CT) showed tumor activity in the left seminal vesicle (Figure 2). Extensive examination for metastases, including chest X-ray film and abdominal computed tomography (CT) showed no abnormalities. Resection of the bilateral seminal vesicles was performed. The left seminal vesicle was obviously swollen (4. × 3.0 × 2.5 cm) and was adhering widely to its surroundings. The resected tumor was a solid encapsulated mass, and the cut surface showed cystic fish-like changes (Figure 3). Although the right seminal vesicle was slightly swollen, there was no sign of tumor involvement.
Figure 1

Magnetic resonance imaging (MRI): an abnormal signal mass in the left seminal vesicle.

Figure 2

Positron emission tomography/computed tomography (PET/CT). There was still tumor activity in the left seminal vesicle.

Figure 3

The resected specimen with the tumor showing capsulated appearance and cut surface cystic, fish-like changes.

Histological evaluation of the resected specimen exhibited a malignant tumor composed of neoplastic cells proliferating in a microcystic or reticular pattern of growth. The neoplastic cells had highly atypical middle- or large-sized nuclei, with Schiller-Duval bodies partially mimicking papillary structures (Figure 4). Immunohistochemical stain for α-fetoprotein was positive (Figure 5). Histological features of the resected specimen were interpreted as a yolk sac tumor. The cutting edge of the left seminal vesicle was not involved. Plus, the right seminal vesicle was free of the tumor. Therefore, we diagnosed his disease as a yolk sac tumor originating in the left seminal vesicle. After surgery, serum AFP decreased to 29.7 ug/l, yet it increased to 79.43 ug/l at four weeks. After the surgery, the patient received four cycles of chemotherapy consisting of bleomycin (30 U D-2, 9, and 16), cisplatin (30 mg/m2 for five consecutive days), and etoposide (100 mg/m2 for five consecutive days). On completion of the chemotherapy, serum AFP was found to have decreased to 53.24 ug/l and remained stable. However, at week 6 after chemotherapy, serum AFP again elevated to 184.9 ug/ml. Positron emission tomography (PET) of the pelvis revealed lymph node metastases in the region of the left iliac vessels. Thus, resection of the pelvic lymph nodes was performed. Enlarged lymph nodes were not found in the areas of the external iliac, internal iliac and obturator. The left side of the prostate was fixed to the pelvic wall. Histological evaluation of the specimens exhibited proliferation in the left obturator lymph tissues but showed no evidence of lymphatic metastasis. Fibrous connective tissue outside the bladder was infiltrated by lymphocytes.
Figure 4

Histopathology of the resected specimen. A. The resected specimen was a malignant tumor composed of neoplastic cells proliferating in a microcystic or reticular growth pattern. B. Neoplastic cells with highly atypical middle-or large-sized nuclei and Schiller-Duval bodies partially mimicking papillary structures

Figure 5

Immunohistochemical stain for alpha-fetoprotein was positive

On the postoperative Day 3, adjunct radiotherapy was introduced, but the response was not good, with AFP remaining at a high level since then. The patient presented rapid multiple systemic metastases and died of cachexia one and half years after diagnosis.

Discussion

YST is a malignant germ cell tumor that usually arises in the gonads and is characteristically accompanied by an elevation of the serum α-fetoprotein level. YST is rarely found extragonadally. Case reports have described the occurrences of this entity in the pineal gland, head and neck, mediastinum, lung, stomach, liver, omentum, retroperitoneum, prostate, intrarenal, vagina, vulva, urachus and presacral regions [26].

The typical morphologic structures of endodermal sinus pattern known as sinuses of Duval, Schiller-Duval bodies, or glomerulus-like structures, superficially resemble immature renal glomeruli [7]. The three sensitive diagnostic markers for yolk sac tumor are alpha-fetoprotein, glypican-3 and SALL4 [3, 7].

The histogenesis of extragonadal YST remains controversial. These tumors appear to arise from germ cells misplaced during embryogenesis, and malignant transformation leads to primary germ cell tumors at extragonadal sites [8].

Due to the rarity of the extragonadal YST, there is no detailed description of its epidemiology and its clinical features in particular. Additionally, due to the particularly aggressive nature of YST, the information derived from germ cell tumor (GCT) studies may have limited applicability. From the case reports we have, the age distribution of extragonadal YST, similar to that of the testicular tumors, appears to be bimodal with an early peak in early infancy and a later peak in adolescence. YST may grow to a large size with no or relatively few symptoms, and the symptoms may vary due to origin sites. The majority of YSTs produce high levels of AFP, which helps in monitoring the response to the treatment. In the past, YSTs were nearly uniformly fatal, regardless of the primary location. However, the survival rate of YST patients has been significantly improved because of the application of Cisplatin-based multiagent chemotherapy [16, 9].

In our case, the patient had no history of swollen testes or testicular atrophy and had normal testes on palpation.Also, a scrotal sonography was performed and revealed no abnormalities in either side of the testes. With spatial resolution boosted by a high-frequency transducer, a testicular tumor may be nonpalpable but still visible sonographically [10, 11]. Sonographic findings range from echogenic foci or hypoechoic areas and heterogeneous lesions to microlithiasis and macrocalcifications [11, 12]. It should be noted that normal sonographic findings were more frequent before 1990 [11]. Therefore, we did not consider the diagnosis of the primary testicular tumor regressed with metastasis in the seminal vesicle. However, since the testes were not resected, we could not completely exclude this possibility without histological evaluation.

A correct diagnosis was made as late as half a year after the symptoms appeared due to the unspecific symptoms (gross hematuria and hemospermia) and rarity of the site of extragonadal YST (the seminal vesicle). This may be one of the contributors to the poor prognosis. From the clinical courses of this patient, we can see that the patient’s general response to the treatment is not very good as compared with recent reports. Jay P. Shah [13] reported a five-year survival rate of 65%. The possible reasons for the poor prognosis of our patient were the advanced age, the race and the site of the original tumor. The median age at the time of diagnosis of YSTs is 18, occurrence after 30 is exceptional [14], and prognosis in the infancy cohort is better than that in the adolescent cohorts. The age of our patient (38) may be a contributor to the poor diagnosis. In Jay P. Shah’s report, African-Americans had poorer survival compared with Caucasians. Yu-juwei Hse [15] reported the treatment results in Chinese patents with nonseminomatous extragonadal germ cell tumor (NSEGCT) are not as good as in patients in Western countries. Saxman et al.[16] reported the experience with chemotherapy in Indians with NSEGCT. Only 5 of 73 patients (7%) were long-term disease-free survivors after chemotherapy. More investigations need to be done to determine whether race is one of the contributors to the poor prognosis of EGCT. Several reports showed that EGCT in mediastina has a worse outcome than EGCT in other sites [1517]. To our knowledge, there is no report about YST primarily arising in the seminal vesicle. The seminal vesicle as the site of origin contributes to the patient’s poor prognosis.

Conclusions

We present a rare case of yolk sac tumor originating in the left seminal vesicle. Extragonadal YST is an aggressive germ cell tumor, and the treatment results are still unsatisfactory. More investigations are warranted to define the optimal treatment.

Consent

Written informed consent was obtained from the patient’s elder brother for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Notes

Abbreviations

YST: 

yolk sac tumor

AFP: 

α-fetoprotein

CT: 

computed tomography

MRI: 

magnetic resonance imaging

PSA: 

prostate-specific antigen

PET/CT: 

Positron emission tomography/computed tomography

GCT: 

germ cell tumor

EGCT: 

extragonadal germ cell tumor

NSEGCT: 

nonseminomatous extragonadal germ cell tumor.

Declarations

Authors’ Affiliations

(1)
Department of Urology, Fudan University Shanghai Cancer Center
(2)
Department of Oncology, Shanghai Medical College, Fudan University
(3)
Department of Pathology, Fudan University Shanghai Cancer Center

References

  1. Bosl GJ, Motzer RJ: Testicular germ-cell cancer. N Engl J Med. 1997, 337: 242-253. 10.1056/NEJM199707243370406. Erratum in: N Engl J Med 1997, 337:1403View ArticlePubMedGoogle Scholar
  2. Toner GC, Geller NL, Lin SY, Bosl GJ: Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features. Cancer. 1991, 67: 2049-2057.PubMedGoogle Scholar
  3. Mei K, Liu A, Allan RW, Wang P, Lane Z, Abel TW, Wei L, Cheng H, Guo S, Peng Y, Rakheja D, Wang M, Ma J, Rodriguez MM, Li J, Cao D: Diagnostic utility of SALL4 in primary germ cell tumors of the central nervous system: a study of 77 cases. Mod Pathol. 2009, 22: 1628-1636. 10.1038/modpathol.2009.148.View ArticlePubMedGoogle Scholar
  4. Saxman SB, Nichols CR, Einhorn LH: Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience. J Clin Oncol. 1994, 12: 1390-1393.PubMedGoogle Scholar
  5. Cao D, Liu A, Wang F, Allan RW, Mei K, Peng Y, Du J, Guo S, Abel TW, Lane Z, Ma J, Rodriguez M, Akhi S, Dehiya N, Li J: RNA-binding protein LIN28 is a marker for primary extragonadal germ cell tumors: an immunohistochemical study of 131 cases. Mod Pathol. 2011, 24: 288-296. 10.1038/modpathol.2010.195.View ArticlePubMedGoogle Scholar
  6. Gupta R, Mathur SR, Arora VK, Sharma SG: Cytologic features of extragonadal germ cell tumors: a study of 88 cases with aspiration cytology. Cancer. 2008, 114: 504-511. 10.1002/cncr.23983.View ArticlePubMedGoogle Scholar
  7. Talerman A: Germ cell tumors of the ovary. Blaustein's Pathology of the Female Genital Tract. Edited by: Kurman RJ. 2002, New York: Springer-Verlag, 967-1033. 5Google Scholar
  8. Albers P, Düsseldorf : 10th edition of the European Association of Urology Guidelines. Edited by: Parsons KF. 2010, The European Association of UrologyGoogle Scholar
  9. Bukowski RM, Wolf M, Kulander BG, Montie J, Crawford ED, Blumenstein B: Alternating combination chemotherapy in patients with extragonadal germ cell tumors. A Southwest Oncology Group study. Cancer. 1993, 71: 2631-2638. 10.1002/1097-0142(19930415)71:8<2631::AID-CNCR2820710831>3.0.CO;2-G.View ArticlePubMedGoogle Scholar
  10. Prim J: Spontanheilung eines bösartigen wahrschein-lich chorionepitheliomatosen: gewaches im hoden. Arch Pathol Anat. 1927, 265: 239-241. 10.1007/BF01894164.View ArticleGoogle Scholar
  11. Tasu J-P, Faye N, Eschwege P, Rocher L, Bléry M: Imaging of burned-out testis tumor: five new cases and review of the literature. J Ultrasound Med. 2003, 22: 515-521.PubMedGoogle Scholar
  12. Kebapci M, Can C, Isiksoy S, Aslan O, Oner U: Burned-out tumor of the testis presenting as supraclavicular lymphadenopathy. Eur Radiol. 2002, 12: 371-373. 10.1007/s003300101038.View ArticlePubMedGoogle Scholar
  13. Shah JP, Kumar S, Bryant CS, Ali-Fehmi R, Malone JM, Deppe G, Morris RT: A population-based analysis of 788 of yolk sac tumors: a comparison of males and females. Int J Cancer. 2008, 123: 2671-2675. 10.1002/ijc.23792.View ArticlePubMedGoogle Scholar
  14. Robova H, Rob L, Hrehorcak M, Zoban P, Prusa R: Endodermal sinus tumor diagnosed in pregnancy: a case report. Int J Gynecol Cancer. 2007, 17: 914-933. 10.1111/j.1525-1438.2007.00850.x.View ArticlePubMedGoogle Scholar
  15. Hse Y-J, Pai L, Chen YC, Ho CL, Kao WY, Chao TY: Extragonadal germ cell tumor in Taiwan: an analysis of treatment results of 59 patients. Cancer. 2002, 95: 766-774. 10.1002/cncr.10738.View ArticleGoogle Scholar
  16. Bokemeyer C, Hartmann JT, Fossa SD, Droz JP, Schmol HJ, Horwich A, Gerl A, Beyer J, Pont J, Kanz L, Nichols CR, Einhorn L: Extragonadal germ cell tumors: relation to testicular neoplasia and management options. APMIS. 2003, 111: 49-59. 10.1034/j.1600-0463.2003.11101081.x. discussion 59–63View ArticlePubMedGoogle Scholar
  17. Rosti G, De Giorgi U, Wandt H, Lioure B, Leyvraz S, Kolbe K, Papiani G, Ballardini M, Kulekci A, Demirer T, Solid Tumours Working Party: First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party. Bone Marrow Transplant. 2004, 34: 1033-1037. 10.1038/sj.bmt.1704704.View ArticlePubMedGoogle Scholar

Copyright

© Yao et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement